DMD and cardiomyopathy: Adeno-associated virus (AAV)-mediated systemic administration of microdystrophin, which functionally substitutes for dysfunctional dystrophin in DMD, demonstrates amelioration of muscle pathology, enhancement of contractile force, and attenuation of cardiomyopathy in preclinical models.